Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07486960 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)
A Phase 2 study, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
NCT07486960 is a Phase 2 study that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 140 participants.
The verdict
NCT07486960, a Phase 2 study, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
Study Summary
Researchers are looking for new ways to treat Psoriatic Arthritis (PsA). This study will help find out if a study medicine called tulisokibart (MK-7240) can treat symptoms of active PsA. This study assesses the efficacy, safety, and tolerability of tulisokibart in adult participants with active PsA. In this study, researchers will look at different doses of tulisokibart. Researchers want to learn if at least one of the study doses of tulisokibart works better than a placebo to lessen PsA symptoms. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of the study medicine.
Interventions
- DRUG Placebo
- DRUG Tulisokibart
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2026-04-20 |
| Est. Completion | 2030-01-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07486960
The ClinicalTrials.gov registry entry for NCT07486960 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07486960 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07486960 about?
NCT07486960 is a clinical study titled "Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)". Researchers are looking for new ways to treat Psoriatic Arthritis (PsA). This study will help find out if a study medicine called tulisokibart (MK-7240) can treat symptoms of active PsA. This study assesses the efficacy, safety, and tolerability of tulisokibart in adult participants with active PsA....
What is the current status of trial NCT07486960?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2026-04-20. Estimated completion is 2030-01-11.
What interventions are being tested in trial NCT07486960?
The interventions under investigation include: Placebo (DRUG), Tulisokibart (DRUG).
Who is sponsoring clinical trial NCT07486960?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.